As president, Donald Trump is sure to get the most promising treatments for COVID-19 - but only a handful have shown promise to bat back the devastating disease.
Since announcing that he and first lady Melania Trump announced they had tested positive for coronavirus late Thursday night, the president has begun exhibiting mild 'cold-like' symptoms, according to the New York Times.
His symptoms were confirmed by Dr Sean Conley, but the White House physician has not revealed what, if any treatments the president might receive.
Currently, only the antiviral remdesivir and plasma from COVID-19 survivors have been given emergency use authorization to treat coronavirus by the Food and Drug Administration (FDA).
Because Trump is 74, obese and has less than perfect heart health, he is at risk for more severe coronavirus, and more likely than a younger, healthier adult to need treatment.
And with those risks, drugs to keep the president's blood pressure and cholesterol may be as important to how well he copes with COVID-19 - and his odds of surviving the infection - as innovative treatments for coronavirus will be.
DailyMail.com breaks down how the president might be treated for COVID-19.
President Trump currently has mild symptoms of coronavirus, meaning he may be a good candidate for treatment with the antiviral remdesivir (file)
So far, the Food and Drug Administration (FDA) has only given emergency use authorization (EUA) - an expedited, interim form of approval with a lower standard - just three therapeutics to treat coronavirus.
The agency has already revoked its EUA for hydroxychloroquine, the malaria drug that Trump infamously promoted, and took himself as an unproven preventive.
That leaves just two authorized treatments: remdesivir and convalescent plasma.
REMDESIVIR COULD HELP KEEP THE PRESIDENT'S VIRAL LOAD LOW AND SHORTEN HIS ILLNESS
Gilead's antiviral remdesivir is the most well-proven treatment for coronavirus that has received the FDA's emergency approval.
Remdesivir was originally developed to treat Ebola, but failed to help patients in clinical trials.
The shelved, experimental drug was dusted off and repurposed by its developer, Gilead, when the coronavirus pandemic emerged earlier this year.
The drug appears to help stop the replication of viruses like coronavirus and Ebola alike.
It's not entirely clear how the drug accomplishes this feat, but it seems to stop the genetic material of the virus, RNA, from being able to copy itself.
That, in turn, stops the virus from being able to proliferate further inside the patient's body.
Gilead's antiviral remdesivir is the most well-proven treatment for coronavirus that has received the FDA's emergency approval
In April, Gilead announced the results of a clinical trial testing the drug in people severely ill with coronavirus.
Half of the 397 patients, who were sick enough to need additional oxygen, but not to be placed on ventilators, improved within 10 days of a five-day treatment course and those who were on a 10-day regimen were better by the eleventh day.
More than half of the patients were discharged from the hospital within two weeks.
The National Institutes of Health's (NIH) own 1,063-person trial of remdesivir showed that severely ill patients who received the drug recovered 30 percent more quickly than those who got a placebo.
Patients who got remdesivir were also 40 percent less likely to die of COVID-19, compared to those who did not get the drug.
Data has since suggested that the drug works best when given early and may be best suited to treat mild to moderate cases. Remdesivir may only be moderately helpful to severely ill patients, falling short of a life-saving treatment.
As President Trump has only had mild symptoms so far, he may be a good candidate for treatment with remdesivir.
Gilead also announced Thursday that the drug is on the cusp of full FDA approval, which would make it the first and only therapeutic to get regulators' seal of approval so far.
FDA OFFICIALS APPROVED PLASMA FROM COVID-19 SURVIVORS TO TREAT THOSE STILL SICK AMID OUTCRY THAT ITS BENEFITS MAY BE LIMITED
Plasma is rich in immune cells developed by the body as it combats coronavirus and some studies have suggested that transfusions of the blood component can bolster the immune systems of the sick.
Plasma is rich in immune cells developed by the body as it combats coronavirus
Specifically, plasma contains antibodies, immune cells that the body generates in response to particular pathogens, including SARS-CoV-2, once a person has had the infection.
FDA officials issued an EUA for so-called convalescent plasma in August, but it was met with criticism from scientists - including NIH